KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Short-term Investments (2016 - 2023)

Historic Short-term Investments for BeOne Medicines (ONC) over the last 9 years, with Q4 2023 value amounting to $2.6 million.

  • BeOne Medicines' Short-term Investments fell 9960.92% to $2.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.6 million, marking a year-over-year decrease of 9960.92%. This contributed to the annual value of $2.6 million for FY2023, which is 9960.92% down from last year.
  • Per BeOne Medicines' latest filing, its Short-term Investments stood at $2.6 million for Q4 2023, which was down 9960.92% from $107.0 million recorded in Q3 2023.
  • In the past 5 years, BeOne Medicines' Short-term Investments ranged from a high of $3.3 billion in Q4 2020 and a low of $2.6 million during Q4 2023
  • Moreover, its 5-year median value for Short-term Investments was $1.0 billion (2022), whereas its average is $1.4 billion.
  • Its Short-term Investments has fluctuated over the past 5 years, first skyrocketed by 79620.9% in 2020, then plummeted by 9960.92% in 2023.
  • Quarter analysis of 5 years shows BeOne Medicines' Short-term Investments stood at $364.7 million in 2019, then surged by 796.21% to $3.3 billion in 2020, then crashed by 31.41% to $2.2 billion in 2021, then tumbled by 70.33% to $665.3 million in 2022, then tumbled by 99.61% to $2.6 million in 2023.
  • Its Short-term Investments stands at $2.6 million for Q4 2023, versus $107.0 million for Q3 2023 and $105.7 million for Q2 2023.